Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRX Pharmaceuticals Inc (NRXP) provides investors and healthcare professionals with critical updates on novel therapies for central nervous system disorders and pulmonary diseases. This page aggregates official press releases, clinical trial developments, and regulatory milestones related to the company’s NMDA platform and ketamine-based treatments.
Visitors gain access to verified information about NRX-100 and NRX-101 – investigational therapies targeting suicidal depression and bipolar disorder – along with strategic initiatives through subsidiary HOPE Therapeutics. The resource prioritizes clarity in explaining complex biopharmaceutical concepts while maintaining scientific precision.
Key content includes updates on Fast Track designations, New Drug Application progress, and innovations in preservative-free drug formulations. The curated news collection serves as a decision-making tool for tracking the company’s progress in addressing unmet medical needs through rigorous clinical research.
Bookmark this page for streamlined access to NRX Pharmaceuticals’ latest developments in interventional psychiatry and small-molecule therapeutics. Check regularly for authoritative updates on pipeline advancements and regulatory strategy execution.
NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary, HOPE Therapeutics, has signed a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, a premier interventional psychiatry clinic in western Florida.
Cohen and Associates, founded by Dr. Rebecca Cohen, will serve as a foundational clinic in the Sarasota-Bradenton region. The clinic specializes in treating suicidal depression, PTSD, and other CNS disorders through various treatments including ketamine, Spravato, and Transcranial Magnetic Stimulation (TMS). The acquisition is expected to be immediately accretive to revenue and EBITDA.
NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, announced its selection to present at the Wall Street Conference on May 21, 2025 in Palm Beach, Florida. Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx and Co-CEO of HOPE Therapeutics, will provide a company update focusing on progress towards FDA approval of NRX-100 (preservative-free ketamine) and upcoming acquisitions of HOPE clinics specializing in treatment of suicidal depression, PTSD, and related disorders.
The conference, which will host six presenting companies, is expected to attract over 1,000 attendees representing more than $1 trillion in investment capital.
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has secured a term sheet with Universal Capital for $7.8 million in debt financing. Combined with a previously announced strategic investment, HOPE is set to receive $10.3 million in total acquisition capital.
The funding will support HOPE's national expansion strategy through the acquisition of interventional psychiatry clinics, starting with Dura Medical, Kadima, and NeuroSpa. These clinics specialize in neuroplastic treatments, including ketamine and transcranial magnetic stimulation (TMS), for treating severe depression, PTSD, and related conditions. The clinics currently serve veterans through Veterans Health Administration contracts and the general public.
Universal Capital shares HOPE's vision of establishing a nationwide network of mental health clinics and plans to participate in future funding as additional acquisitions are identified.HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, CA. Kadima, a profitable clinic specializing in interventional psychiatry, will serve as the clinical model for HOPE's nationwide treatment network. The institute is a leading research site for CNS and psychedelic therapies, offering treatments including ketamine, Spravato, and TMS for conditions like suicidal depression and PTSD.
Dr. David Feifel, Kadima's founder and a recognized expert in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer post-acquisition. The acquisition is expected to be accretive to revenue and EBITDA for both NRx and HOPE, subject to closing conditions and financing finalization.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has scheduled its first quarter 2025 financial results announcement for May 15, 2025, after market close. The company will release results through a press release available on their investor relations website, followed by a conference call at 4:30 PM ET.
Interested parties can access the conference call via webcast on the company's website or by telephone using the following dial-in numbers: +1-800-717-1738 (domestic) or +1-646-307-1865 (international).